ASND sentiment intelligence

J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating

J.P. Morgan has reiterated its Buy rating on Ascendis Pharma A/S (ASND.US) stock. The analyst maintained a price target of $170.00, suggesting potential upside for investors.

Tone

Positive 77/100

Event

Analyst action

Published

19 Jun 2026 19:09

Source

富途牛牛

Ascendis Pharma A/S (ASND) Earnings Forecast: Future EPS & Revenue Growth Estimates

Ascendis Pharma A/S (ASND) currently has an earnings forecast score of 8.95 and an average price target of $254.00 from 20 analysts, with a "Strong Buy" rating. Analysts expect the company's next quarter revenue to be $384.76M and EPS to be $1.70, a significant improvement from t

Tone

Positive 74/100

Event

Earnings

Published

18 Jun 2026 01:09

Source

TradingKey

Ascendis Pharma (NASDAQ: ASND) nets $187.5M from FDA PRV sale

Ascendis Pharma (NASDAQ: ASND) announced the sale of its U.S. Rare Pediatric Disease Priority Review Voucher (PRV) for $187.5 million in cash to an undisclosed buyer. This PRV was granted following the FDA approval of YUVIWEL® (navepegritide) in February 2026. The transaction is

Tone

Positive 65/100

Event

Regulatory and legal

Published

17 Jun 2026 21:09

Source

Stock Titan

Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $326

Wells Fargo has reiterated its Buy rating for Ascendis Pharma A/S (ASND.US) and maintained its price target of $326. This indicates the firm's continued confidence in the company's stock performance.

Tone

Positive 76/100

Event

Analyst action

Published

17 Jun 2026 16:10

Source

Moomoo

Ascendis Pharma A/S (ASND) Stock Analysis: A Biotech Powerhouse with 36.97% Potential Upside

Tone

Positive 66/100

Event

Market update

Published

15 Jun 2026 09:15

Source

DirectorsTalk Interviews

Long-term TransCon PTH data from Ascendis Pharma (ASND) show sustained benefits

Ascendis Pharma reported positive 3.5-year data from its Phase 3 PaTHway Trial of TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism. The study demonstrated sustained efficacy, safety, and improvements in quality of life and key biochemical markers. Patients ma

Tone

Positive 95/100

Event

Market update

Published

15 Jun 2026 10:09

Source

Stock Titan

(ASND) Risk Channels and Responsive Allocation

This article analyzes Ascendis Pharma A/s (NASDAQ: ASND) using AI models, identifying a positive near-term sentiment while noting potential mid-term weakness within a long-term strong context. It outlines specific institutional trading strategies including position trading, momen

Tone

Positive 63/100

Event

Market update

Published

13 Jun 2026 20:38

Source

Stock Traders Daily

Ascendis Pharma Reports Sustained Efficacy and Safety of TransCon PTH in Phase 3 PaTHway Trial for Hypoparathyroidism After Three and a Half Years

Ascendis Pharma announced positive long-term results from its Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. The treatment demonstrated sustained efficacy and safety over three and a half years, showing significant improvements in

Tone

Positive 73/100

Event

Earnings

Published

13 Jun 2026 20:10

Source

Quiver Quantitative

Hormone shot helps hypoparathyroidism patients cut daily calcium and vitamin D

Ascendis Pharma announced positive long-term Phase 3 data for their drug TransCon PTH, showing sustained efficacy and safety for adults with hypoparathyroidism. The treatment helped 86% of patients meet a multi-component endpoint and allowed 100% to achieve independence from acti

Tone

Positive 92/100

Event

Market update

Published

13 Jun 2026 19:38

Source

Stock Titan

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions

Ascendis Pharma A/S announced Week 182 data from its Phase 3 PaTHway Trial, demonstrating that TransCon PTH (palopegteriparatide) provided sustained efficacy and safety in adults with hypoparathyroidism over three and a half years. The treatment replicated the systemic actions of

Tone

Positive 90/100

Event

Market update

Published

13 Jun 2026 16:00

Source

GlobeNewswire

Ascendis Pharma Says TransCon PTH Shows Sustained Efficacy at 5 Years

Ascendis Pharma announced that its investigational drug, TransCon PTH, demonstrated sustained efficacy and safety for up to 5 years in patients with hypoparathyroidism. Data from the Phase 2 PaTH Forward study showed that a majority of patients maintained independence from conven

Tone

Positive 86/100

Event

Regulatory and legal

Published

12 Jun 2026 13:09

Source

Moomoo

Five-year TransCon PTH trial results reported by Ascendis Pharma (ASND)

Ascendis Pharma A/S reported positive 5-year (Week 266) results from its Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. The trial demonstrated sustained efficacy and safety, replicating the systemic actions of natural parathyro

Tone

Positive 75/100

Event

Earnings

Published

12 Jun 2026 09:40

Source

Stock Titan

Ascendis boasts of long-term Yorvipath data for hypoparathyroidism

Ascendis Pharma announced new long-term data from a Phase 2 trial of its hypoparathyroidism treatment, Yorvipath (palopegteriparatide). The data indicate sustained efficacy over five years, with the hormone replacement therapy showing a beneficial impact on target organs.

Tone

Positive 71/100

Event

Analyst action

Published

11 Jun 2026 20:39

Source

Seeking Alpha

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Ascendis Pharma announced 5-year Phase 2 data from its PaTH Forward Trial, demonstrating sustained efficacy and safety of TransCon PTH in adults with hypoparathyroidism. The treatment replicated endogenous PTH actions, showing benefits in kidney function, bone mineral density, an

Tone

Positive 92/100

Event

Market update

Published

11 Jun 2026 19:39

Source

GlobeNewswire

5-year trial: drug frees most hypoparathyroidism patients from supplements

Ascendis Pharma reported positive 5-year Phase 2 data for TransCon PTH in adults with hypoparathyroidism, showing sustained efficacy and safety. The drug normalized calcium levels, improved kidney function, and enhanced quality of life, with 82% of patients meeting the multi-comp

Tone

Positive 71/100

Event

Market update

Published

11 Jun 2026 19:39

Source

Stock Titan

Ascendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy

Tone

Positive 82/100

Event

Market update

Published

09 Jun 2026 07:00

Source

Market source

Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Weakness

Ascendis Pharma (ASND) has seen its stock price fall recently, raising questions about its valuation. Despite a fair value estimate of $342.08 per share, suggesting it is 38.5% undervalued, this relies on ambitious growth and profitability assumptions for 2029, including €2.6 bil

Tone

Positive 70/100

Event

Market update

Published

09 Jun 2026 01:38

Source

Market source

Ascendis Pharma A/S to Present Latest Data on Endocrinology Rare Disease Programs at ENDO 2026

Ascendis Pharma A/S will present new data from its Endocrinology Rare Disease programs at the ENDO 2026 annual meeting in Chicago from June 13-16, 2026. The presentations will include findings on hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency, highlig

Tone

Positive 72/100

Event

Market update

Published

08 Jun 2026 21:10

Source

Quiver Quantitative

TD Asset Management Inc Has $49.90 Million Position in Ascendis Pharma A/S $ASND

TD Asset Management Inc reduced its stake in Ascendis Pharma A/S by 21% in Q4, but still holds a significant position of

Tone

Positive 69/100

Event

Deals and strategy

Published

07 Jun 2026 00:39

Source

MarketBeat

Ascendis Pharma A/S Stock 12‑Month Price Target Raised to $295.6, Implies 40% Upside

Ascendis Pharma A/S (ASND) has seen its average 12-month price target increased by analysts to $295.6, up from $293.61. This new target suggests a potential upside of approximately 40% from its June 5 closing price. The consensus among 18 analysts remains a "Buy" rating for the s

Tone

Positive 80/100

Event

Analyst action

Published

06 Jun 2026 16:40

Source

TradingView

Ascendis Pharma reports trial data on achondroplasia treatment

Ascendis Pharma A/S announced positive subgroup analysis results from its ApproaCH Trial for achondroplasia treatment, showing sustained growth improvements in children aged 5 and older. The company recently received FDA approval for TransCon CNP (YUVIWELL) and is awaiting Europe

Tone

Positive 73/100

Event

Earnings

Published

04 Jun 2026 15:40

Source

Investing.com